BF
BBIO icon

BOK Financial’s BridgeBio Pharma BBIO Stock Holding History

BOK Financial’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Sell
4,895
-1,429
-23% -$100K 0.01% 610
2026
Q1 		$470K Sell
6,324
-1,041
-14% -$75.5K 0.01% 554
2025
Q4 		$563K Sell
7,365
-4,018
-35% -$264K 0.01% 524
2025
Q3 		$591K Sell
11,383
-7,443
-40% -$363K 0.01% 534
2025
Q2 		$813K Sell
18,826
-84
-0.4% -$3.06K 0.01% 474
2025
Q1 		$654K Buy
+18,910
New +$638K 0.01% 502

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

BOK Financial's BBIO Position: Q2 2026 in Review

BOK Financial reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $100K and leaving 4,895 shares worth $365K. The position accounts for 0.01% of the portfolio, ranked #610.

BOK Financial first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $813K in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • BOK Financial held 4,895 shares of BridgeBio Pharma worth $365K as of Q2 2026.
  • BOK Financial sold 1,429 BridgeBio Pharma shares in Q2 2026, an estimated $100K.
  • BridgeBio Pharma made up 0.01% of BOK Financial's portfolio in Q2 2026, its #610 holding.
  • BOK Financial first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • BOK Financial's BridgeBio Pharma position peaked at $813K in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.